Citigroup Inc. Acquires 108,809 Shares of CareDx, Inc (NASDAQ:CDNA)

Citigroup Inc. raised its holdings in CareDx, Inc (NASDAQ:CDNA) by 49.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 328,563 shares of the company’s stock after buying an additional 108,809 shares during the period. Citigroup Inc. owned about 0.61% of CareDx worth $3,003,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Rhumbline Advisers lifted its position in CareDx by 0.9% in the 1st quarter. Rhumbline Advisers now owns 55,130 shares of the company’s stock valued at $2,039,000 after acquiring an additional 481 shares in the last quarter. Neuberger Berman Group LLC grew its holdings in CareDx by 1.0% during the first quarter. Neuberger Berman Group LLC now owns 59,225 shares of the company’s stock worth $2,191,000 after buying an additional 587 shares in the last quarter. Arizona State Retirement System raised its position in CareDx by 4.3% in the 4th quarter. Arizona State Retirement System now owns 15,084 shares of the company’s stock valued at $172,000 after buying an additional 621 shares during the last quarter. EFG Asset Management Americas Corp. lifted its stake in CareDx by 6.8% during the 4th quarter. EFG Asset Management Americas Corp. now owns 11,924 shares of the company’s stock valued at $136,000 after acquiring an additional 760 shares in the last quarter. Finally, Lazard Asset Management LLC grew its stake in shares of CareDx by 32.0% in the 1st quarter. Lazard Asset Management LLC now owns 3,225 shares of the company’s stock worth $119,000 after acquiring an additional 782 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CDNA shares. BTIG Research lowered shares of CareDx from a “buy” rating to a “neutral” rating in a research note on Thursday, May 11th. HC Wainwright reiterated a “neutral” rating on shares of CareDx in a research note on Wednesday, August 9th. Raymond James raised shares of CareDx from a “market perform” rating to an “outperform” rating and set a $12.00 price objective on the stock in a research report on Tuesday, August 15th. Finally, StockNews.com started coverage on shares of CareDx in a report on Thursday, August 17th. They issued a “hold” rating on the stock. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $13.60.

Insider Transactions at CareDx

In other CareDx news, Director Peter Maag sold 5,000 shares of CareDx stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $10.34, for a total transaction of $51,700.00. Following the completion of the sale, the director now directly owns 309,657 shares in the company, valued at $3,201,853.38. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other CareDx news, Director Peter Maag sold 5,000 shares of the firm’s stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $10.34, for a total transaction of $51,700.00. Following the sale, the director now owns 309,657 shares in the company, valued at $3,201,853.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Reginald Seeto sold 14,268 shares of the company’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $8.76, for a total value of $124,987.68. Following the completion of the transaction, the insider now owns 500,873 shares of the company’s stock, valued at $4,387,647.48. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 33,173 shares of company stock valued at $313,243. 4.20% of the stock is owned by corporate insiders.

CareDx Price Performance

NASDAQ CDNA opened at $9.73 on Tuesday. The company’s 50 day simple moving average is $9.67 and its two-hundred day simple moving average is $9.41. CareDx, Inc has a 1 year low of $6.22 and a 1 year high of $20.91. The stock has a market capitalization of $527.07 million, a PE ratio of -6.24 and a beta of 0.95.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.10. The company had revenue of $70.30 million during the quarter, compared to analyst estimates of $56.40 million. CareDx had a negative return on equity of 19.84% and a negative net margin of 27.15%. On average, research analysts anticipate that CareDx, Inc will post -2.25 EPS for the current year.

CareDx Profile

CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.